Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy

Muscle & Nerve
M H BarnettJ G McLeod

Abstract

The role of cyclosporin A (CsA) in the treatment of resistant chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was retrospectively reviewed in 19 patients who had failed to respond adequately to corticosteroids, plasmapheresis, intravenous immunoglobulin, and in some cases other immunosuppressive agents. Patients were subdivided into progressive or relapsing types according to the course of disease and response to therapy graded at follow-up by clinical and electrophysiological criteria. In the progressive group, the mean disability status declined from 3.8+/-0.7 to 1.8+/-1.1 grades on a 5-grade scale following CsA therapy (P<0.001). In the relapsing group, the mean annual incidence of relapse declined from 1.0+/-0.5 to 0.2+/-0.4 after commencement of CsA (P<0.05). Dose-dependent, reversible nephrotoxicity was the most serious complication of therapy, and necessitated cessation of CsA in 2 patients. In conclusion, CsA is an efficacious and, with appropriate monitoring, safe therapy for patients with CIDP.

References

Apr 1, 1979·Australian and New Zealand Journal of Medicine·G L Walker
Nov 1, 1976·Journal of the Neurological Sciences·A D Rosen, E F Vastola
Apr 1, 1976·Journal of the Neurological Sciences·J W Prineas, J G McLeod
Apr 1, 1992·Journal of Neuroimmunology·P A LudowykC R Parish
Jun 1, 1992·Journal of the Neurological Sciences·E Nobile-OrazioG Scarlato
Jan 1, 1992·Journal of Neuroimmunology·A A IlyasS D Cook
Sep 1, 1991·Journal of the Neurological Sciences·A A IlyasS D Cook
Mar 1, 1991·Journal of the Neurological Sciences·A A IlyasS D Cook
Apr 1, 1990·Journal of Neurology, Neurosurgery, and Psychiatry·S J HodgkinsonJ G McLeod
Dec 21, 1989·The New England Journal of Medicine·B D Kahan
May 1, 1988·Annals of Neurology·A A IlyasG M McKhann
Feb 20, 1986·The New England Journal of Medicine·P J DyckC Swanson
Nov 1, 1985·Archives of Neurology·K P Johnson, G Belendiuk
Oct 24, 1970·Lancet·G M YuillL A Liversedge
Jan 1, 1969·Brain : a Journal of Neurology·P K ThomasR L Hewer
Jun 1, 1970·Journal of Neurology, Neurosurgery, and Psychiatry·W B MatthewsR D Hughes
Aug 1, 1984·Journal of Neuroimmunology·R A HughesH Thompson
Jan 1, 1981·Annals of Neurology·M C Dalakas, W K Engel
Aug 1, 1995·Brain : a Journal of Neurology·J M SpiesJ D Pollard
Dec 1, 1994·Therapeutic Drug Monitoring·R G MorrisJ E Ray
Jan 1, 1993·Annual Review of Medicine·J R Mendell
Feb 1, 1996·Journal of Neurology, Neurosurgery, and Psychiatry·W MahattanakulD R Cornblath
Aug 1, 1996·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·M SuthanthiranT B Strom

❮ Previous
Next ❯

Citations

Jul 19, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·M OdakaN Yuki
Mar 18, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·D FialhoR A C Hughes
Aug 12, 2009·Pediatric Neurology·M Ozlem HergünerSakir Altunbaşak
Apr 4, 2007·Revue neurologique·A Echaniz-Laguna
Dec 16, 1998·Current Opinion in Neurology·H P HartungJ D Pollard
May 23, 2002·Clinical Neuropharmacology·Andrew J Gordon, Matthew N Meriggioli
Dec 11, 1999·Current Opinion in Neurology·R D Hadden, R A Hughes
Mar 29, 2012·Rinshō shinkeigaku = Clinical neurology·Akiko TakeuchiHidenao Sasaki
Apr 9, 2013·Current Treatment Options in Neurology·Mazen M Dimachkie, Richard J Barohn
Jan 1, 2003·Current Neurology and Neuroscience Reports·David S Saperstein, Richard J Barohn
Apr 1, 2005·The New England Journal of Medicine·Hubertus KöllerHans-Peter Hartung
Apr 21, 2010·Expert Review of Clinical Immunology·Elspeth J Hutton, Michael P T Lunn
Aug 17, 2011·Nature Reviews. Neurology·Marinos C Dalakas, UNKNOWN Medscape
Aug 17, 2001·Annals of Neurology·R HughesUNKNOWN Inflammatory Neuropathy Cause and Treatment (INCAT) Group
Nov 30, 2000·Current Treatment Options in Neurology·K C Gorson, V Chaudhry
Sep 22, 2005·Current Rheumatology Reports·Lisa D Hobson-Webb, Peter D Donofrio
Jan 19, 2011·Current Treatment Options in Neurology·Glenn Lopate, Alan Pestronk
Oct 19, 2017·Neurodegenerative Disease Management·Yusuf A Rajabally
Nov 8, 2018·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Cecilia Ostman, Bobby Chacko
Jun 9, 2001·Transplantation·R A El-SabroutC T Van Buren
Aug 5, 2003·Current Treatment Options in Neurology·Jonathan S. Katz, David S. Saperstein
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Jean-Marc Léger
Jan 16, 2007·Current Neurology and Neuroscience Reports·Thomas B Toothaker, Thomas H Brannagan
Mar 1, 2006·Journal of Clinical Neuromuscular Disease·Norman LatovJean Michel Vallat
Jun 23, 2011·Therapeutic Advances in Neurological Disorders·Min-Suk YoonRalf Gold
Apr 15, 2008·Expert Opinion on Biological Therapy·F Eftimov, I N van Schaik
Aug 25, 2017·Journal of Neurology·Kalliopi PitarokoiliChristiane Schneider-Gold
Aug 21, 2003·Muscle & Nerve·Peter D Donofrio
Mar 15, 2006·Expert Review of Neurotherapeutics·Masaaki Odaka
Jul 16, 2009·Expert Opinion on Pharmacotherapy·Laurent Magy, Jean-Michel Vallat
Mar 1, 2003·Expert Review of Neurotherapeutics·Ryan L Kaplan, James W Albers
Sep 14, 2011·Current Treatment Options in Neurology·Hugh J McMillanPeter B Kang
Nov 10, 2012·Therapeutic Advances in Neurological Disorders·Kenneth C Gorson
Feb 9, 2006·Current Treatment Options in Neurology·Eduardo Adonias De Sousa, Thomas H Brannagan
Jan 23, 2021·Journal of Nephrology·Irene FaravelliClaudio Ponticelli
Jul 31, 2021·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Peter Y K Van den BerghHaluk A Topaloglu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.